Congratulations to Levron Cardiovascular Ltd, an ICI Innovation Award Finalists, on an enlightening presentation!
Meir Kenigsztein presented Levron, an Alon Medtech portfolio company, and it’s groundbreaking technology for the first time in front of a captive audience.
Dr. Eckhouse is the founder, owner and Chairman of Alon Medtech.
An inventor, active entrepreneur and investor in the field of medical devices and medical technology,
Until July 2017 Dr. Eckhouse was the chairman of Syneron Medical Ltd. (Nasdaq ELOS) which he co-founded in 2001, until it was acquired by APAX partners.
Dr. Eckhouse is the chairman and co-founder of Epitomee medical, Rapid Medical, Theranica, RealView. Dr. Eckhouse was a co-founder, chairman and CEO of ColorChip from 2001 to 2003; Was a co-founder of Ventor Medical Technologies and its Chairman until it was acquired by Medtronic in 2009 for $325M
Dr Eckhouse was the founder, chairman and CEO of Lumenis (former ESC) from its inception in 1992 until 1999. He took the company public on Nasdaq in 1996 and raised more than $250M in 3 public offerings, the company reached a valuation of more than $1B returning to its investors more than X120 on their investment in the company.
Dr Eckhouse is the inventor of IPL (Intense Pulsed Light) technology which he brought to market in 1994 in ESC and is the most popular non-invasive energy based technology for a broad range of non-invasive medical aesthetic applications.
Dr Eckhouse holds a BSc in physics from the Technion – Israeli Institute of Technology and a Ph.D. in physics from the University of California at Irvine. He is the author of more than 60 US registered patents and a few hundred international patents and published more than 50 papers in leading refereed journals and conferences.
VP Business Development
Mr. Mansour is a co-founder of Alon Medtech.
Assaf brings extensive experience and expertise in investments due diligence, examines the commercial feasibility, strategic planning, management and business development.
Assaf maintains a long-term commitment to the portfolio companies by working closely with the entrepreneurs and assisting them with business development and keep supporting them after they have become independent and successful companies
Mr. Mansour is serving as an active board member in Sofwave Medical (TASE:SOFW) and several more medical companies.
Prior to founding Alon Medtech, Mr. Mansour worked in high-tech companies for more than 12 years’, with particular expertise in managing international customers. In his last positions he served as account program manager at Comverse and TTI Telecom, where he was responsible for customers across North America and Europe..
Mr. Mansour holds a BSc in Industrial Engineering and an MBA from the Ben-Gurion University of the Negev.
Mr. Eden has joined Alon Medtech as Chief Financial Officer in 2014. He has over 20 years of experience in VC’s investments and management of high growth technology companies.
Miki has vast experience in M&A and IPO transactions, fund raising, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from seed stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.
Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.
Haya works closely with the Alon Medtech Chairman, CEO and management team on business intelligence and Marketing strategy, managing all marketing activities of Alon.
Prior to Alon Medtech, Haya was Marketing Manager leading strategy, budget and execution at a prominent IT integration company; Account manager at a leading PR firm; and Legal intern at Herzog Fox & Neeman – Capital Markets and Securities Dep, worked with public companies in all Corporate and Securities Law matters, engaged in public and private offerings of securities, worked on M&A transactions.
Haya holds an LLB degree form Kiryat Ono Academic College.
Dr. Ruthie Amir joined Alon Medtech Ventures as the chief medical officer in 2018.
Prior to joining Alon Medtech Dr. Amir served as the director of clinical research and the head of the regulatory department of Syneron Candela from 2008 to 2017.
Dr. Ruthie Amir graduated from Ben Gurion University Medical School in 1989. From 1996-2000, she completed her post-doctoral fellowship in the Department of Human Genetic, at Baylor College of Medicine, Houston, USA where she worked on the genetic basis of Rett Syndrome. Between 2000-2003 she completed a post-doctoral fellowship in the Department of Cell Biology, Faculty of Medicine, Technion.
Dr Zilberstein is responsible for managing Alon Medtech, including choosing projects, advancing them into companies and guiding their scientific activity.
Dr Zilberstein leads the marketing strategy together with the companies and forges scientific and commercial ties with external groups. She serves as a board member in the portfolio companies of Alon MedTech.
Dr Zilberstein has more than 20 years’ experience in the medical device industry; Vast experience in investments in the Healthcare and nanotech fields.
She served as GM of Maayan Ventures, an early stage investment fund; an active director/chairperson of numerous early stage companies; CTO & BDD of several entrepreneurial medical oriented companies and technological incubators. Dr Zilberstein is the inventor of a several innovations, in the field of optical sensors and cancer therapy.
Dr Zilberstein holds a BSc in chemistry. MSc in chemical physics and PhD in life science, from the Weizmann Institute of Science, She has published numerous scientific articles.
Michael joined Alon Medtech as Chief Financial Officer in 2014. He has over 20 years of management experience in overall financial & commercial strategy, fund raising and capital allocation, M&A transactions, investor relations, governance and risk management. Michael is a Senior executive with vast experience in investing and managing high-growth technology companies, due diligence processes, post-acquisition integration and active management and control over global subsidiaries. He has extensive knowledge of business, legal and tax aspects relating to investments, management and control of portfolio companies in different fields.
Prior to joining Alon Medtech, Michael served as a Financial, Commercial and Operational executive in leading high-growth technology companies such as: Convergin, a provider of service broker platforms to mobile operators, acquired by Oracle; Hobart (Prof Shlomo Ben Haim’s investment group) specializing in active management of its health-care portfolio companies from startup stage through acquisition and IPOs; and Aura Investment a publicly traded investment company focused on early stage investments and active management of technology companies.
Michael has a B.A in accounting and business administration and a Master of Law (LL.M) from Bar Ilan University and is also an Israeli certified public accountant.
Anat is overseeing the portfolio companies financial aspects including accounting, budget and tax. Anat has over 10 years experience in providing professional services across a broad range of finance areas.
Prior to Alon MedTech, Anat held senior finance positions for international cooperations, privately-held companies and Hi-Tech companies and also served as a professional department manager for over 8 years.
Anat is an Israeli certified public accountant and holds a B.A in Business Administration and Accounting and a M.B.A (Tax specialization) from the College of Management.
Handling all legal aspects of Alon Medtech Ventures and its portfolio companies including fundraising, corporate law, labor law, clinical trials, commercial transaction, regulatory review as well as advising board of directors and C level executives on ongoing day-to-day issues.
Etel has over 13 years of legal counseling experience starting from commercial litigation through in-house counseling.
Etel holds LL.B from The Interdisciplinary Center in Herzliya and LL.M from the Tel Aviv Berkeley Executive program.
For the past twelve years Dr. Makover has managed venture capital investments in the biotech/ medical devices field (Tzina Bio-Perspective, Proseed VC). Previously she held senior management positions in life sciences companies focusing on drugs, diagnostics and tissue engineering.
Dr Makover holds a joint Ph.D degree in life sciences from Columbia University (USA) and Weizmann Institute of Science, (Israel) and did post- doctoral research at the Weizmann Institute in Israel. DR. Makover also holds an MBA degree from Bar-Ilan University.
Dr. Makover is serving as a director of the board of six companies including public traded ones
Experienced Chief Executive Officer with a demonstrated history of working in the medical device industry and Pharma industry. Skilled in the Cardio Vascular, Neurosurgery, Spine, Minimal invasive surgeries, Medical Devices, High Tech Home Care businesses. Strong background in strategy and business development in the Medtech and Biotech industry.
Judith currently serves as a board member at a number of startups. She is a partner at HM Medical Solution LTD.
Judith has been until recently Medtronic’s Israel CEO for more than 12 years and an executive management member of Medtronic BCEGI region. Before joining Medtronic, Judith held senior management positions at Teva Ltd